Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase IIb Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics announced that the Independent Data Monitoring Committee recommended the continuation of enrollment as planned into VIRAGE, a multinational, Phase IIb, randomized, open-label, controlled clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy as a first-line therapy for patients with metastatic PDAC.